EZ Cap™ mCherry mRNA (5mCTP, ψUTP): Cap 1-Modified Red Fluorescent Reporter

Executive Summary: EZ Cap™ mCherry mRNA (5mCTP, ψUTP) is a synthetic messenger RNA (~996 nt) encoding the monomeric red fluorescent protein mCherry, derived from Discosoma sp. DsRed. This mRNA features a Cap 1 structure enzymatically added with Vaccinia capping machinery, along with 5-methylcytidine (5mCTP) and pseudouridine (ψUTP) modifications to enhance translation and stability while suppressing innate immune responses (I Guri-Lamce et al., 2024, DOI). The product is supplied at ~1 mg/mL in 1 mM sodium citrate (pH 6.4) and includes a poly(A) tail for optimal translation initiation. Designed as a molecular marker for cell component localization and reporter assays, it is stable at ≤ -40°C and minimizes immunogenicity. APExBIO is the original manufacturer of this research-grade reagent (product page).

Biological Rationale

mCherry is a monomeric red fluorescent protein (RFP) with excitation/emission maxima at 587/610 nm, frequently used as a molecular marker and reporter in live-cell imaging (FPbase). The mCherry gene is derived from the Discosoma sp. DsRed protein through site-directed mutagenesis, resulting in improved brightness and photostability. The length of the mCherry coding sequence is approximately 711 base pairs, with full synthetic mRNA constructs, including UTRs and poly(A) tail, reaching ~996 nucleotides (Addgene). Fluorescent protein mRNAs serve as essential reporter genes, enabling visualization of gene expression, protein localization, and cell tracking in diverse biological contexts. Modified nucleotides such as 5mCTP and ψUTP reduce activation of pattern recognition receptors (PRRs), thereby suppressing RNA-mediated innate immune activation and increasing mRNA stability in mammalian systems (Guri-Lamce et al., 2024).

Mechanism of Action of EZ Cap™ mCherry mRNA (5mCTP, ψUTP)

• The Cap 1 structure is enzymatically added using Vaccinia virus capping enzyme (VCE), GTP, S-adenosylmethionine (SAM), and 2'-O-methyltransferase, closely mimicking eukaryotic mRNA capping and enhancing translation efficiency (DOI).
• 5-methylcytidine (5mCTP) and pseudouridine (ψUTP) are incorporated throughout the mRNA, which reduces recognition by Toll-like receptors (e.g., TLR3, TLR7, TLR8), mitigating innate immune activation and promoting translation (Guri-Lamce et al., 2024).
• A poly(A) tail is present, facilitating ribosome recruitment and increasing translational output.
• The mRNA is delivered in 1 mM sodium citrate buffer at pH 6.4, a condition that preserves RNA integrity during storage and handling.
• Upon cellular delivery (e.g., lipid nanoparticles, electroporation), the mRNA is translated in the cytoplasm, yielding cytosolic mCherry protein with strong red fluorescence (excitation 587 nm, emission 610 nm).

Evidence & Benchmarks

• Lipid nanoparticles can efficiently deliver synthetic mRNAs, including those with nucleotide modifications (5mCTP, ψUTP), into mammalian cells without triggering significant innate immune responses (Guri-Lamce et al., 2024).
• Cap 1 capping increases translational efficiency by >2-fold compared to Cap 0 in mammalian cells (DOI).
• 5mCTP and ψUTP modifications extend mRNA half-life in vitro by up to 1.5–2× relative to unmodified mRNA (I Guri-Lamce et al., 2024, Table 1).
• EZ Cap™ mCherry mRNA (5mCTP, ψUTP) produces robust, photostable red fluorescence within 4–6 hours post-transfection, sustained for ≥24 hours in vitro (APExBIO).
• The product's full-length mRNA (996 nt) and buffer formulation ensure stability at ≤ -40°C for at least 12 months (APExBIO).

Applications, Limits & Misconceptions

EZ Cap™ mCherry mRNA (5mCTP, ψUTP) is optimized for use as a reporter gene in molecular biology and cell biology. It is compatible with a variety of delivery modalities, including lipid nanoparticles (LNPs), electroporation, and microinjection. The product is ideal for:

• Live-cell imaging of gene expression and protein localization using red fluorescence (587/610 nm).
• Molecular marker studies for cell component positioning, lineage tracing, and fate mapping.
• Assaying transfection efficiency in optimization and validation experiments.
• Benchmarking mRNA delivery technologies and immune evasion strategies.

Common Pitfalls or Misconceptions

• Not a DNA-based reporter: This product is mRNA, not a plasmid or DNA-based vector; it does not integrate into the genome and yields only transient expression.
• Immunogenicity not eliminated: While 5mCTP and ψUTP modifications suppress innate immune activation, they do not guarantee complete absence of immune response, especially at high doses.
• Temperature sensitivity: Storage above -40°C can result in rapid mRNA degradation and loss of activity.
• Not suitable for in vivo gene therapy: This reagent is for research use only and not for human therapeutic applications.
• Fluorescence wavelength fixed: mCherry fluorescence peaks at 587/610 nm and cannot be tuned to other colors.

For a detailed mechanistic analysis, this article provides deeper insights into mRNA stability and immune evasion, while this comparison focuses on fluorescent protein expression optimization. The current article extends these with quantitative benchmarks and specific storage/handling parameters.

Workflow Integration & Parameters

• Concentration: Supplied at ~1 mg/mL in 1 mM sodium citrate, pH 6.4.
• Storage: ≤ -40°C; avoid freeze-thaw cycles.
• Delivery: Compatible with lipid nanoparticles (LNPs), electroporation, and microinjection (Guri-Lamce et al., 2024).
• Visualization: Detect red fluorescence at excitation 587 nm, emission 610 nm.
• Expression window: Detectable mCherry protein within 4–6 hours post-transfection, lasting ≥24 hours in vitro.
• Controls: Include non-fluorescent mRNA or unmodified mCherry mRNA as negative/benchmark controls.

This article clarifies how the Cap 1 and nucleotide modification strategy in EZ Cap™ mCherry mRNA (5mCTP, ψUTP) improves reproducibility and minimizes immune confounders, extending the benchmarks highlighted in this review.

Conclusion & Outlook

EZ Cap™ mCherry mRNA (5mCTP, ψUTP) represents a next-generation tool for fluorescent protein expression with minimized immunogenicity and maximized stability. Its Cap 1 capping, modified nucleotides, and optimized buffer support robust, reproducible reporter gene assays. For molecular biology workflows requiring precise localization or real-time tracking, this reagent sets a performance benchmark (APExBIO product page). Ongoing advances in mRNA technology and delivery will likely further expand its utility in research and preclinical models.